Liu et al. [12] found that FSIP1 directly binded to the intracellular domain of HER2 and inhibited the expression of FSIP1 in HER2-positive breast cancer cells, resulting in decreased cell proliferation, increased apoptosis, and decreased cell migration and invasion capability through co-immunoprecipitation and microthermal atrophy. This evidence concerns the gene ERBB2 and breast carcinoma.